Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
"While hand-wringing about the competitive landscape will continue to come and go, we continue to believe thatShares of Dutch biotechnology company Argenx SE ADR (NASDAQ:ARGX) jumped this week after an impressive third-quarter earnings print. Analysts shortly raised their price targets on the stock.
荷蘭生物技術公司Argenx SE ADR（納斯達克：ARGX）的股價本週上漲，令人印象深刻的第三季度收益即將公佈。分析師們很快提高了他們對該股的價格目標。
The Argenx Analysts: The following analysts released notes following argenx's earnings:
Argenx分析師：以下分析師在Argenx發佈收益後發佈了研究報告：
- Piper Sandler analyst Allison M. Bratzel, reiterating an Overweight rating, raising its price target from $553 to $620.
- Oppenheimer analyst Leland Gershell, reiterating an Outperform rating, raising its price target from $560 to $646.
- Truist analyst Joon Lee, reiterating a Buy rating, raising its price target from $540 to $660.
- Citizens JMP analyst Jason N. Butler, reiterating an Outperform rating, raising its price target from $497 to $606.
- 派傑投資分析師Allison M. Bratzel重申股票的超配評級，將其價格目標從553美元上調至620美元。
- Oppenheimer分析師Leland Gershell重申股票的多頭評級，將其價格目標從560美元上調至646美元。
- Truist分析師Joon Lee重申股票的買入評級，將其價格目標從540美元上調至660美元。
- Citizens JMP分析師Jason N. Butler重申股票的多頭評級，將其價格目標從497美元上調至606美元。
Piper Sandler: Bratzel noted that the rescinding of Argentx's cash burn guidance implies an increase in the company's revenue outlook in coming quarters.
派傑投資：Bratzel指出，Argentx撤銷的現金燃燒指引暗示了該公司未來幾個季度營業收入前景的提高。
"While hand-wringing about the competitive landscape will continue to come and go, we continue to believe that
ARGX has set an extremely high bar with Vyvgart's clinical profile and has solidified themselves as dominant players in the gMG space (and soon-to-be CIDP space)," the analyst said.
“雖然人們對競爭格局的擔憂會持續出現和消退，但我們仍然相信
派傑投資指出，ARGX在Vyvgart的臨床資料方面設定了非常高的標準，並已經鞏固了自己作爲gMG領域主導者（以及即將成爲CIDP領域主導者）的地位。
Accordingly, Bratzel raised revenue estimates in the near term.
因此，Bratzel在短期內提高了營業收入預期。
Oppenheimer: Gershell noted the potential to beat long-term patient estimates.
Oppenheimer：Gershell指出有超過長期患者預估的潛力。
"With >3,000 total Vyvgart prescribers and ~10K treated patients, ARGX appears on track to achieve its Vision 2030 goal of 50K patients on therapy—and we see potential to exceed this."
「擁有超過3,000名總Vyvgart處方醫生和約1萬名接受治療的患者，ARGX似乎正在順利實現其2030年5萬患者在治療中的目標，而且我們看到超越這一目標的潛力。」
The analyst also believes that Argentx is sufficiently managing expenses, pipeline and commercial demands.
分析師還相信Argentx在管理費用、管道和商業需求方面做得足夠好。
Truist: Lee is encouraged by Argentx's immunology and inflammation pipeline.
Truist：Lee對Argentx的免疫學和炎症管道感到鼓舞。
"Most importantly, in our view, ARGX has the most enviable I&I pipeline in the industry with multiple data read-outs over the next 12-18 months."
「最重要的是，在我們看來，ARGX在行業板塊擁有最令人羨慕的I&I管道，未來12-18個月將有多個數據公佈。」
The analyst will closely watch global expansion in Japan, the European Union, China and Canada in 2025.
該分析師將密切關注2025年在日本、歐盟、中國和加拿大的全球擴張。
Citizens JMP: Butler highlighted Argentx's strong quarter, success in its CIDP launch and ongoing
global expansion of VYVGART.
Citizens JMP：巴特勒突出了Argentx在其強勁季度中的表現，以及其CIDP產品推出和全球擴張的成功
VYVGARt的全球擴張。
"We view the initial launch of VYVGART Hytrulo in CIDP as robust, with over 300 CIDP patients currently on treatment as of the end of 3Q24," the analyst said. "85-90% of patients on drug transitioned from IVIg, supporting the market switch potential. 25% of CIDP prescribers are first time prescribers and some also prescribed for MG."
「我們認爲CIDP中VYVGARt Hytrulo的初期推出表現良好，在截至第3季度結束時，有超過300名CIDP患者正在接受治療，」分析師表示。「85-90%的服用該藥物的患者從IVIg轉換過來，支持市場的轉變潛力。25%的CIDP處方醫生是首次處方醫生，有些還爲MG患者開具了處方。」
Butler also noted management's "Vision 2030" goal of five new molecules in Phase 3, 10 labeled indications, and 50k patients.
巴特勒還提到管理層的「Vision 2030」目標，即在3期試驗中推出五種新分子，獲得10個標註適應症，並擁有5萬患者。
Price Action: Shares of Argentx rose over 6% on Thursday and, at the time of writing, is up over 1% on Friday.
股價走勢：Argentx股價週四上漲超過6％，截至撰寫時，週五上漲超過1％。
Also Read:
還閱讀：
- Exxon Q3 Earnings: $11.3 Billion Cost Savings, Rising Production, Dividend Hike And More
- 埃克森Q3收益：113億美元的成本節省，生產增長，股息上調等等
譯文內容由第三人軟體翻譯。
